ArticleMetabolomics : Official journal of the Metabolomic Society2025
Non-targeted metabolomics can identify disease-specific characteristics of ischemic stroke.
Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionIschemic stroke (IS) is a leading cause of disability and mortality. Metabolomics, in conjunction with machine learning (ML), can be employed to identify potential biomarkers associated with this condition.
objectiveWe aimed to utilize metabolomics to evaluated the potential biomarkers and crucial metabolic pathways linked with IS. Furthermore, to construct a predictive model employing ML algorithms.
methodsWe conducted non-targeted liquid chromatography-tandem mass spectrometry-based plasma analysis on 786 study participants (discovery set IS/control group = 198/198; external validation set IS patients/control group = 195/195). The aim was to identify differential metabolites and examine metabolic pathways potentially related to the etiology of IS using pathway enrichment analysis. Feature variables were screened using the Least Absolute Shrinkage and Selection Operator and random forest algorithm. We employed XGBoost to construct prediction models for these feature variables, and utilized various evaluation indicators to assess model performance. This was subsequently confirmed in an independent external validation set.
resultsIn the comparison between the IS group and the control group, 200 differential metabolites were detected. Notable dysbiotic pathways encompass arachidonic acid metabolism and folate biosynthesis among others. Four significant metabolites were further investigated to differentiate between the IS group and the control group: Calcitroic acid, Diguanosine tetraphosphate, PC (P-18:0/P-18:1(9Z)), and Deoxycholic acid. The XGBoost model exhibited an AUC of 1.000 for the training set and 0.992 for the test set in the discovery columns, while the external independent validation set recorded an AUC of 0.941.
conclusionOur study unveiled the metabolic landscape of IS, identified four biomarkers, and developed a prediction model that effectively differentiates between the IS group and the control group based on these four biomarkers.
Indexed as
Identifiers
41324824What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.